Relay Therapeutics Inc
RLAY
Get informed when a big investor buys or sells
+ Follow
Current Fair Value
107.9% downsideOvervalued by 107.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.25 Billion |
|---|---|
| Enterprise Value | $3.08 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.61 |
| Beta | 1.75 |
| Outstanding Shares | 179,849,137 |
Return
| Return on Equity | -42.47% |
|---|---|
| Return on Assets | -38.98% |
| Return on Invested Capital | -43.47% |
Valuation & Multiples
| P/E Ratio | -11.82 |
|---|---|
| PEG | 241.4 |
| Price to Sales | - |
| Price to Book Ratio | 6.22 |
| Enterprise Value to Revenue | 288.06 |
| Enterprise Value to EBIT | -10.56 |
| Enterprise Value to Net Income | -12 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.05 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0677▲ 2.18% |
|---|---|
| Total Calls | 1,102,700▲ 77.08% |
| Total Puts | 74,700▲ 161.19% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 106.73%▲ 6.05% |
|---|---|
| Total Invested | $1.82B▲ 24.08% |
| Investors Holding | 246▲ 17.00% |
ESG Score
No data
About Relay Therapeutics Inc
2,020 employeesRelay Therapeutics, Inc. operates as a biotechnology company. The Company develops durgs for the treatment of cancer. Relay Therapeutics serves customers in the United States.
Relevant Senate Committees
Oversees Medicare and Medicaid reimbursement rates and tax policy, which determine the commercial viability and pricing of new cancer drugs.
Determines the annual budgets for the FDA and NIH, directly impacting the speed of drug reviews and the availability of research funding.
Primary regulator of the FDA and NIH; directly influences the drug approval process and federal funding for biomedical research.
Oversees patent law and intellectual property rights, which are the fundamental drivers of valuation and competitive advantage for biotech firms.
Drug pricing and accessibility for cancer treatments are central to this committee's oversight, creating significant headline and regulatory risk.